SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

SAN

80.23

-0.12%↓

UCB

274.7

+1.85%↑

SHL.DE

37.73

+1.13%↑

ARGX

680.8

+1.01%↑

VIE

34.99

+0.52%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

25.54 0.95

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

25.3

Max

25.86

Põhinäitajad
By Trading Economics
Sissetulek	-5.4M
Müük	27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	1.1M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+24.61% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	20. mai 2026

Turustatistika
By TradingEconomics
Turukapital	1.3B
Eelmine avamishind	24.59
Eelmine sulgemishind	25.54

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. apr 2026, 17:04 UTC

Suurimad hinnamuutused turgudel

FDA Rejects Replimune's Melanoma Drug for a Second Time

11. apr 2026, 00:00 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Big Yachts, Big Bucks -- Barrons.com

10. apr 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10. apr 2026, 21:01 UTC

Tulu

Cango Inc.: Files Annual Report on Form 20-F With SEC

10. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. apr 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10. apr 2026, 20:10 UTC

Omandamised, ülevõtmised, äriostud

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10. apr 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10. apr 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10. apr 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. apr 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10. apr 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10. apr 2026, 18:25 UTC

Market Talk

Uudisväärsed sündmused

Precious Metals Finish With Weekly Gains -- Market Talk

10. apr 2026, 18:05 UTC

Market Talk

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10. apr 2026, 17:31 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10. apr 2026, 17:26 UTC

Tulu

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10. apr 2026, 17:10 UTC

Market Talk

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10. apr 2026, 17:00 UTC

Uudisväärsed sündmused

Construction Business Taking a Hit From Iran Conflict -- WSJ

10. apr 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

10. apr 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

10. apr 2026, 16:12 UTC

Tulu

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10. apr 2026, 16:11 UTC

Tulu

Partners Group: Traditional Programs Contributed $3.3B

10. apr 2026, 16:10 UTC

Tulu

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10. apr 2026, 16:10 UTC

Tulu

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10. apr 2026, 16:10 UTC

Tulu

Partners Group 1Q New Client Demand $8.3B

10. apr 2026, 16:09 UTC

Tulu

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10. apr 2026, 15:54 UTC

Omandamised, ülevõtmised, äriostud

Plenitude Completes Acquisition of Acea Energia

10. apr 2026, 15:38 UTC

Market Talk

Global Energy Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

24.61% tõus

12 kuu keskmine prognoos

Keskmine 32 EUR 24.61%

Kõrge 32 EUR

Madal 32 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.